Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026

ONCOLYTICS BIOTECH INC

Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
Primary endpoint is ORR; secondary endpoints include PFS, OS, safety, and biomarker analysis; first site expected this month.
Prior REO 022 study showed median OS 27 months and PFS 16.6 months, vs 11.2 and 5.7 months for standard of care.
Pelareorep combination recently granted FDA Fast Track Designation for this indication.
Lead investigator is Dr. Sanjay Goel (Rutgers Cancer Institute); preliminary data by year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.